Table 1

Patient and tumor characteristics of evaluable breast cancer patients treated with placebo or with 4-HPR and tamoxifen

CharacteristicsTreatment
Placebo (n = 20), n (%)4-HPR and tamoxifen (n = 16), n (%)
Age (yrs)
 Median5650
 Range39–7329–76
ER status
 Positive17 (85)9 (56)
 Negative3 (15)7 (44)
Initial T stage
 Tis3 (15)3 (19)
 T113 (65)9 (56)
 T24 (20)3 (19)
 Atypical ductal hyperplasia0 (0)1 (6)
Nodal status
 N020 (100)15 (94)
 N10 (0)1 (6)
Pathological tumor size
 No greater than 1 cm8 (40)2 (12)
[3 DCIS][2 DCIS]
 Greater than 1 cm12 (60)14 (88)
No. of positive nodes by pathology
 013 (65)8 (50)
 1–32 (10)5 (31)
 4–102 (10)1 (6)
 >101 (5)0 (0)
 No ALNDa2 (10)2 (13)
Modified Black’s nuclear gradeb
 11 (5)1 (6)
 213 (65)7 (44)
 36 (30)7 (44)
 Not gradablec0 (0)1 (6)
Histology of primary tumor
 Invasive ductal with or without DCIS13 (65)10 (62)
 Invasive lobular1 (5)1 (6)
 DCIS3 (15)3 (19)
 Otherd3 (15)2 (13)
  • a Axillary lymph node dissection (ALND) not performed in these patients.

  • b 3 = most anaplastic.

  • c Atypical ductal hyperplasia.

  • d Placebo arm: mucinous carcinoma; mixed invasive ductal, invasive lobular, DCIS; mixed invasive ductal and invasive lobular. Treatment arm: atypical ductal hyperplasia; mucinous carcinoma.